Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Antimicrobial peptide LL-37 and its truncated forms, GI-20 and GF-17, exert spermicidal effects and microbicidal activity against Neisseria gonorrhoeae.

Kiattiburut W, Zhi R, Lee SG, Foo AC, Hickling DR, Keillor JW, Goto NK, Li W, Conlan W, Angel JB, Wang G, Tanphaichitr N.

Hum Reprod. 2018 Dec 1;33(12):2175-2183. doi: 10.1093/humrep/dey315.

PMID:
30357408
2.

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.

Adhikary G, Grun D, Alexander HR, Friedberg JS, Xu W, Keillor JW, Kandasamy S, Eckert RL.

Oncotarget. 2018 Oct 2;9(77):34495-34505. doi: 10.18632/oncotarget.26130. eCollection 2018 Oct 2.

3.

Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation.

Jambrovics K, Uray IP, Keresztessy Z, Keillor JW, Fésüs L, Balajthy Z.

Haematologica. 2019 Mar;104(3):505-515. doi: 10.3324/haematol.2018.192823. Epub 2018 Sep 20.

4.

Mechanisms of Alkyl and Aryl Thiol Addition to N-Methylmaleimide.

Raycroft MAR, Racine KÉ, Rowley CN, Keillor JW.

J Org Chem. 2018 Oct 5;83(19):11674-11685. doi: 10.1021/acs.joc.8b01638. Epub 2018 Sep 19.

PMID:
30180571
5.

Rational design of a highly reactive dicysteine peptide tag for fluorogenic protein labelling.

Strmiskova M, Tsao K, Keillor JW.

Org Biomol Chem. 2018 Aug 29;16(34):6332-6340. doi: 10.1039/c8ob01417e.

PMID:
30131994
6.

A Green BODIPY-Based, Super-Fluorogenic, Protein-Specific Labelling Agent.

Chen Y, Tsao K, Acton SL, Keillor JW.

Angew Chem Int Ed Engl. 2018 Sep 17;57(38):12390-12394. doi: 10.1002/anie.201805482. Epub 2018 Aug 24.

PMID:
30086191
7.

Design of a glutamine substrate tag enabling protein labelling mediated by Bacillus subtilis transglutaminase.

Oteng-Pabi SK, Clouthier CM, Keillor JW.

PLoS One. 2018 May 30;13(5):e0197956. doi: 10.1371/journal.pone.0197956. eCollection 2018.

8.

Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death.

Basso M, Chen HH, Tripathy D, Conte M, Apperley KYP, De Simone A, Keillor JW, Ratan R, Nebbioso A, Sarno F, Altucci L, Milelli A.

ChemMedChem. 2018 Feb 6;13(3):227-230. doi: 10.1002/cmdc.201700601. Epub 2018 Jan 18.

PMID:
29286587
9.

Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Akbar A, McNeil NMR, Albert MR, Ta V, Adhikary G, Bourgeois K, Eckert RL, Keillor JW.

J Med Chem. 2017 Sep 28;60(18):7910-7927. doi: 10.1021/acs.jmedchem.7b01070. Epub 2017 Sep 14.

10.

Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.

De Simone A, Bartolini M, Baschieri A, Apperley KYP, Chen HH, Guardigni M, Montanari S, Kobrlova T, Soukup O, Valgimigli L, Andrisano V, Keillor JW, Basso M, Milelli A.

Eur J Med Chem. 2017 Oct 20;139:378-389. doi: 10.1016/j.ejmech.2017.07.058. Epub 2017 Jul 25.

PMID:
28810189
11.

Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.

Kerr C, Szmacinski H, Fisher ML, Nance B, Lakowicz JR, Akbar A, Keillor JW, Lok Wong T, Godoy-Ruiz R, Toth EA, Weber DJ, Eckert RL.

Oncogene. 2017 May 25;36(21):2981-2990. doi: 10.1038/onc.2016.452. Epub 2016 Dec 12.

12.

Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition.

Apperley KYP, Roy I, Saucier V, Brunet-Filion N, Piscopo SP, Pardin C, De Francesco É, Hao C, Keillor JW.

Medchemcomm. 2016 Dec 5;8(2):338-345. doi: 10.1039/c6md00565a. eCollection 2017 Feb 1.

13.

Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.

Monteagudo A, Ji C, Akbar A, Keillor JW, Johnson GVW.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):942-947. doi: 10.1016/j.bbrc.2016.11.137. Epub 2016 Nov 27.

14.

Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.

Fisher ML, Kerr C, Adhikary G, Grun D, Xu W, Keillor JW, Eckert RL.

Cancer Res. 2016 Dec 15;76(24):7265-7276. Epub 2016 Oct 25.

15.

Simultaneous analysis of enzyme structure and activity by kinetic capillary electrophoresis-MS.

Mironov GG, Clouthier CM, Akbar A, Keillor JW, Berezovski MV.

Nat Chem Biol. 2016 Nov;12(11):918-922. doi: 10.1038/nchembio.2170. Epub 2016 Sep 5.

PMID:
27595328
16.

The complex role of transglutaminase 2 in glioblastoma proliferation.

Gundemir S, Monteagudo A, Akbar A, Keillor JW, Johnson GVW.

Neuro Oncol. 2017 Feb 1;19(2):208-218. doi: 10.1093/neuonc/now157.

17.

Ring Substituent Effects on the Thiol Addition and Hydrolysis Reactions of N-Arylmaleimides.

Chen Y, Tsao K, De Francesco É, Keillor JW.

J Org Chem. 2015 Dec 18;80(24):12182-92. doi: 10.1021/acs.joc.5b02036. Epub 2015 Dec 3.

PMID:
26595216
18.

Transglutaminase inhibitors: a patent review.

Keillor JW, Apperley KY.

Expert Opin Ther Pat. 2016;26(1):49-63. doi: 10.1517/13543776.2016.1115836. Epub 2015 Nov 24. Review.

PMID:
26560530
19.

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.

Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL.

Oncotarget. 2015 Aug 21;6(24):20525-39.

20.

Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.

Fisher ML, Keillor JW, Xu W, Eckert RL, Kerr C.

Mol Cancer Res. 2015 Jul;13(7):1083-94. doi: 10.1158/1541-7786.MCR-14-0685-T. Epub 2015 May 1.

21.

Inhibitors of tissue transglutaminase.

Keillor JW, Apperley KY, Akbar A.

Trends Pharmacol Sci. 2015 Jan;36(1):32-40. doi: 10.1016/j.tips.2014.10.014. Epub 2014 Dec 12. Review. Erratum in: Trends Pharmacol Sci. 2015 Jun;36(6):417.

PMID:
25500711
22.

Coumarin-based fluorogenic probes for no-wash protein labeling.

Chen Y, Clouthier CM, Tsao K, Strmiskova M, Lachance H, Keillor JW.

Angew Chem Int Ed Engl. 2014 Dec 8;53(50):13785-8. doi: 10.1002/anie.201408015. Epub 2014 Oct 14.

PMID:
25314130
23.

Acyl transfer mechanisms of tissue transglutaminase.

Keillor JW, Clouthier CM, Apperley KY, Akbar A, Mulani A.

Bioorg Chem. 2014 Dec;57:186-97. doi: 10.1016/j.bioorg.2014.06.003. Epub 2014 Jun 25. Review.

PMID:
25035302
24.

Site-specific protein labelling and immobilization mediated by microbial transglutaminase.

Oteng-Pabi SK, Pardin C, Stoica M, Keillor JW.

Chem Commun (Camb). 2014 Jun 25;50(50):6604-6. doi: 10.1039/c4cc00994k.

PMID:
24824734
25.

Continuous enzyme-coupled assay for microbial transglutaminase activity.

Oteng-Pabi SK, Keillor JW.

Anal Biochem. 2013 Oct 15;441(2):169-73. doi: 10.1016/j.ab.2013.07.014. Epub 2013 Jul 19.

PMID:
23877008
26.

Microbial transglutaminase displays broad acyl-acceptor substrate specificity.

Gundersen MT, Keillor JW, Pelletier JN.

Appl Microbiol Biotechnol. 2014 Jan;98(1):219-30. doi: 10.1007/s00253-013-4886-x. Epub 2013 Apr 25.

PMID:
23615739
27.

Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules.

Song Y, Kirkpatrick LL, Schilling AB, Helseth DL, Chabot N, Keillor JW, Johnson GV, Brady ST.

Neuron. 2013 Apr 10;78(1):109-23. doi: 10.1016/j.neuron.2013.01.036.

28.

Real-time monitoring of protein conformational dynamics in solution using kinetic capillary electrophoresis.

Clouthier CM, Mironov GG, Okhonin V, Berezovski MV, Keillor JW.

Angew Chem Int Ed Engl. 2012 Dec 7;51(50):12464-8. doi: 10.1002/anie.201205575. Epub 2012 Nov 6.

PMID:
23132828
29.

Expression, purification and kinetic characterisation of human tissue transglutaminase.

Roy I, Smith O, Clouthier CM, Keillor JW.

Protein Expr Purif. 2013 Jan;87(1):41-6. doi: 10.1016/j.pep.2012.10.002. Epub 2012 Oct 22.

PMID:
23085087
30.

Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells.

Caron NS, Munsie LN, Keillor JW, Truant R.

PLoS One. 2012;7(8):e44159. doi: 10.1371/journal.pone.0044159. Epub 2012 Aug 31.

31.

Site-specific protein propargylation using tissue transglutaminase.

Gnaccarini C, Ben-Tahar W, Mulani A, Roy I, Lubell WD, Pelletier JN, Keillor JW.

Org Biomol Chem. 2012 Jul 21;10(27):5258-65. doi: 10.1039/c2ob25752a. Epub 2012 May 31.

PMID:
22653499
32.

Irreversible inhibitors of tissue transglutaminase.

Keillor JW, Chabot N, Roy I, Mulani A, Leogane O, Pardin C.

Adv Enzymol Relat Areas Mol Biol. 2011;78:415-47. Review. No abstract available.

PMID:
22220480
33.

Inhibition of aminoglycoside-deactivating enzymes APH(3')-IIIa and AAC(6')-Ii by amphiphilic paromomycin O2''-ether analogues.

Szychowski J, Kondo J, Zahr O, Auclair K, Westhof E, Hanessian S, Keillor JW.

ChemMedChem. 2011 Nov 4;6(11):1961-6. doi: 10.1002/cmdc.201100346. Epub 2011 Sep 8. No abstract available.

34.

Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation.

Colak G, Keillor JW, Johnson GV.

PLoS One. 2011 Jan 31;6(1):e16665. doi: 10.1371/journal.pone.0016665.

35.

Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics.

Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW, Kaartinen MT.

PLoS One. 2011 Jan 20;6(1):e15893. doi: 10.1371/journal.pone.0015893.

36.

Incorporation of chlorinated analogues of aliphatic amino acids during cell-free protein synthesis.

Stigers DJ, Watts ZI, Hennessy JE, Kim HK, Martini R, Taylor MC, Ozawa K, Keillor JW, Dixon NE, Easton CJ.

Chem Commun (Camb). 2011 Feb 14;47(6):1839-41. doi: 10.1039/c0cc02879g. Epub 2010 Nov 22.

PMID:
21103555
37.

Dramatic increase of quench efficiency in "spacerless" dimaleimide fluorogens.

Caron K, Lachapelle V, Keillor JW.

Org Biomol Chem. 2011 Jan 7;9(1):185-97. doi: 10.1039/c0ob00455c. Epub 2010 Nov 10.

PMID:
21063632
38.

Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening.

Chabot N, Moreau S, Mulani A, Moreau P, Keillor JW.

Chem Biol. 2010 Oct 29;17(10):1143-50. doi: 10.1016/j.chembiol.2010.06.019.

39.

De novo helical peptides as target sequences for a specific, fluorogenic protein labelling strategy.

Guy J, Castonguay R, Campos-Reales Pineda NB, Jacquier V, Caron K, Michnick SW, Keillor JW.

Mol Biosyst. 2010 Jun;6(6):976-87. doi: 10.1039/b918205e. Epub 2010 Feb 23.

PMID:
20485742
40.

Fluorometric assay for tissue transglutaminase-mediated transamidation activity.

Gnaccarini C, Ben-Tahar W, Lubell WD, Pelletier JN, Keillor JW.

Bioorg Med Chem. 2009 Sep 1;17(17):6354-9. doi: 10.1016/j.bmc.2009.07.031. Epub 2009 Jul 18.

PMID:
19660958
41.

Microwave-assisted synthesis of rhodamine fluorescent tags.

Ben Tahar WB, Keillor JW, Lubell WD.

Adv Exp Med Biol. 2009;611:225-6. No abstract available.

PMID:
19400171
42.

Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.

Pardin C, Roy I, Chica RA, Bonneil E, Thibault P, Lubell WD, Pelletier JN, Keillor JW.

Biochemistry. 2009 Apr 21;48(15):3346-53. doi: 10.1021/bi802021c.

PMID:
19271761
43.

The crystal structure of ATP-bound phosphofructokinase from Trypanosoma brucei reveals conformational transitions different from those of other phosphofructokinases.

McNae IW, Martinez-Oyanedel J, Keillor JW, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD.

J Mol Biol. 2009 Feb 6;385(5):1519-33. doi: 10.1016/j.jmb.2008.11.047. Epub 2008 Dec 3.

PMID:
19084537
44.

Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.

Pardin C, Roy I, Lubell WD, Keillor JW.

Chem Biol Drug Des. 2008 Sep;72(3):189-96. doi: 10.1111/j.1747-0285.2008.00696.x. Epub 2008 Aug 19.

PMID:
18715232
45.

Cinnamoyl inhibitors of tissue transglutaminase.

Pardin C, Pelletier JN, Lubell WD, Keillor JW.

J Org Chem. 2008 Aug 1;73(15):5766-75. doi: 10.1021/jo8004843. Epub 2008 Jun 27.

PMID:
18582115
46.

Kinetic characterization and identification of the acylation and glycosylation sites of recombinant human gamma-glutamyltranspeptidase.

Castonguay R, Halim D, Morin M, Furtos A, Lherbet C, Bonneil E, Thibault P, Keillor JW.

Biochemistry. 2007 Oct 30;46(43):12253-62. Epub 2007 Oct 9.

PMID:
17924658
47.

Convergent preparation and photophysical characterization of dimaleimide dansyl fluorogens: elucidation of the maleimide fluorescence quenching mechanism.

Guy J, Caron K, Dufresne S, Michnick SW, Skene WG, Keillor JW.

J Am Chem Soc. 2007 Oct 3;129(39):11969-77. Epub 2007 Sep 12.

PMID:
17850081
48.

6-hydroxy to 6'''-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3')-IIIa kinase.

Hanessian S, Szychowski J, Campos-Reales Pineda NB, Furtos A, Keillor JW.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3221-5. Epub 2007 Mar 12.

PMID:
17400454
49.

The first crystal structure of phosphofructokinase from a eukaryote: Trypanosoma brucei.

Martinez-Oyanedel J, McNae IW, Nowicki MW, Keillor JW, Michels PA, Fothergill-Gilmore LA, Walkinshaw MD.

J Mol Biol. 2007 Mar 2;366(4):1185-98. Epub 2006 Oct 11.

PMID:
17207816
50.

Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors.

Halim D, Caron K, Keillor JW.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):305-8. Epub 2006 Oct 25.

PMID:
17092716

Supplemental Content

Loading ...
Support Center